RT Journal Article
SR Electronic
T1 Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 338
OP 341
DO 10.2967/jnumed.120.247924
VO 62
IS 3
A1 Regine Kluge
A1 Tim Wittig
A1 Thomas W. Georgi
A1 Lars Kurch
A1 Osama Sabri
A1 W. Hamish Wallace
A1 Tomasz Klekawka
A1 Ana Fernández-Teijeiro
A1 Francesco Ceppi
A1 Jonas Karlén
A1 Jane Pears
A1 Michaela Cepelová
A1 Alexander Fosså
A1 Auke Beishuizen
A1 Lisa Lyngsie Hjalgrim
A1 Dieter Körholz
A1 Christine Mauz-Körholz
A1 Dirk Hasenclever
YR 2021
UL http://jnm.snmjournals.org/content/62/3/338.abstract
AB In first-line treatment of Hodgkin lymphoma (HL), Deauville scores 1–3 define complete metabolic remission. Interim 18F-FDG PET is also used for relapse-treatment adaptation; however, PET response criteria are not validated for relapse treatment. Methods: We performed a pairwise comparative analysis of early response to first- and second-line treatments in 127 patients with classic HL who experienced relapse. The patients participated in the prospective, multicenter EuroNet-PHL-C1 study. Residual uptake was measured retrospectively using the qPET method, a validated semiautomatic quantitative extension of the Deauville score. Empiric cumulative distribution functions of the qPET values were used to systematically analyze the response to first- and second-line treatments. Results: Individual patients responded variably to first- and second-line treatments. However, the empiric cumulative distribution functions of the qPET values from all patients were nearly superimposable. Conclusion: The findings support that first- and second-line treatments in HL do not require different response criteria.